Enlivex (ENLV) Free Cash Flow (2013 - 2025)
Enlivex (ENLV) posted quarterly Free Cash Flow of -$2.8 million for Q4 2025, up 35.28% year-over-year from -$2.0 million in Q4 2024, and down 41.45% quarter-over-quarter from -$1.9 million in Q3 2025.
Enlivex (ENLV) Free Cash Flow (2013 - 2025) Analysis & Trends
Enlivex's Free Cash Flow history runs 13 years deep, the most recent figure standing at -$2.8 million for Q4 2025.
- In Q4 2025, Free Cash Flow rose 35.28% year-over-year to -$2.8 million; the TTM figure through Dec 2025 stood at -$10.5 million (up 20.04% YoY), while the FY2025 annual figure was -$10.5 million, up 20.04% from the prior year.
- Free Cash Flow for Q4 2025 stood at -$2.8 million, down from -$1.9 million in the prior quarter.
- The five-year high for Free Cash Flow was -$1.2 million in Q2 2025, with the low at -$18.5 million in Q4 2022.
- The 5-year median for Free Cash Flow is -$4.4 million (2024), against an average of -$4.9 million.
- The sharpest annual moves came in 2021 and 2024: Free Cash Flow tumbled 364.91% in 2021, then jumped 74.5% in 2024.
- Enlivex's Free Cash Flow stood at -$8.8 million in 2021, then sank by 109.82% to -$18.5 million in 2022, then soared by 68.93% to -$5.7 million in 2023, then gained by 25.9% to -$4.3 million in 2024, then jumped by 35.28% to -$2.8 million in 2025.
- Business Quant data shows ENLV's Free Cash Flow at -$2.8 million in Q4 2025, -$1.9 million in Q3 2025, and -$1.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Enlivex | 4.51 Mn | -1.25 Mn | - | -2.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.75 Mn |
| Dec 31, 2025 | -2.75 Mn |
| Sep 30, 2025 | -1.95 Mn |
| Sep 30, 2025 | -1.95 Mn |
| Jun 30, 2025 | -1.19 Mn |
| Jun 30, 2025 | -1.19 Mn |
| Mar 31, 2025 | -4.59 Mn |
| Mar 31, 2025 | -4.59 Mn |
| Dec 31, 2024 | -4.26 Mn |
| Dec 31, 2024 | -4.26 Mn |
| Sep 30, 2024 | -2.61 Mn |
| Sep 30, 2024 | -2.61 Mn |
| Jun 30, 2024 | -1.78 Mn |
| Jun 30, 2024 | -1.78 Mn |
| Mar 31, 2024 | -4.47 Mn |
| Mar 31, 2024 | -4.47 Mn |
| Dec 31, 2023 | -5.74 Mn |
| Dec 31, 2023 | -5.74 Mn |
| Sep 30, 2023 | -5.41 Mn |
| Sep 30, 2023 | -5.41 Mn |